Clinical trials: Preventive Measures
Hereditary Angioedema (HAE)
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
The main aims of this study are to learn how many people with HAE Type I or Type II are attack-free when treated with lanadelumab in real life.
- Trial name
- INTEGRATED (NCT04861090)
- Where
- 20 sites in Austria, France and 2 more
- Volunteers
- 207 people
- Sponsor
- Takeda
Upper Respiratory Tract Infections
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu.
- Trial name
- NCT00895947
- Testing
- interferon-alpha
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
covid19
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable…
- Trial name
- NCT04435314
- Testing
- Nitazoxanide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Azidus Brasil
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
- Trial name
- ARISE (NCT02483585)
- Testing
- Erenumab
- Where
- 76 sites in United States, Denmark and 6 more
- Volunteers
- 577 people
- Sponsor
- Amgen
Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)
Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line
Primary Objective: To assess the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of Semuloparin [AVE5026] (assessed from the anti-Xa activity of Semuloparin) in children in order to determine the dose to be assessed in a…
- Trial name
- NCT01567904
- Testing
- Semuloparin sodium
- Where
- Hungary
- Volunteers
- 2 people
- Sponsor
- Sanofi
Gout Flares
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis.
- Trial name
- NCT01712204
- Testing
- AC-201, Febuxostat
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- TWi Biotechnology, Inc.
Covid19, SARS (Severe Acute Respiratory Syndrome)
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
- Trial name
- OPV-NA831 (NCT04540185)
- Testing
- Biological: oral polio vaccine, NA-831, Combination of oral polio vaccine and NA-831
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Rabies
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children…
- Trial name
- NCT00708084
- Testing
- CL184, HRIG
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Migraine With Aura, Migraine Without Aura
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache.
- Trial name
- NCT00334178
- Testing
- Laxymig ER (drug)
- Where
- 7 sites in Taiwan
- Volunteers
- 74 people
- Sponsor
- Lotus Pharmaceutical
Venous Thromboembolism
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
Primary objective: To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd Secondary…
- Trial name
- NCT00077753
- Testing
- enoxaparin sodium
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 4,726 people
- Sponsor
- Sanofi
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk…
- Trial name
- OSCAR-US (NCT04979780)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Where
- United States
- Volunteers
- 3,708 people
- Sponsor
- Bayer
Treatment of Bleeding, Prophylaxis of Bleeding
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
Researchers are looking for a better way to treat hemophilia A. Hemophilia A is a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood.
- Conditions
- Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
- Trial name
- Alfa-PROTECT (NCT05147662)
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- 18 sites in United States, Argentina and 5 more
- Volunteers
- 36 people
- Sponsor
- Bayer
Infectious Disease, Bacterial Infections
Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients
The purpose of this study is to determine whether the antibacterial protein P128 is (i) safe and well tolerated in healthy volunteers and in chronic kidney diseases patients on dialysis, (ii) is it effective in reducing the nasal…
- Trial name
- NCT01746654
- Testing
- P128-0.1 mg, P128-0.3 mg, P128-1.0 mg
- Where
- Singapore
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GangaGen, Inc.
Bladder Cancer
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Bladder cancer is the fourth reason of neoplasia in our environment, there are 25 new cases diagnosed per 100,000 inhabitants each year.
- Trial name
- NCT03982797
- Testing
- Instillation of IMUNO BCG Moreau RJ
- Where
- 15 sites in Spain
- Volunteers
- 306 people
- Sponsor
- Biofabri, S.L
Migraine
A Study of Prophylaxis for Migraine Patients With Topiramate in India
The purpose of this study is to evaluate the safety and effectiveness of topiramate in preventing migraine among Indian participants requiring prophylaxis (measure taken to maintain health and prevent the spread of disease).
- Trial name
- PROMPT-IN (NCT01836874)
- Testing
- No intervention
- Volunteers
- 209 people
- Sponsor
- Janssen-Cilag Ltd.
Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
The primary purpose of this study is to assess the rate of early discontinuation from randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason other than confirmation of the negative HIV…
- Trial name
- PEPDar (NCT01516970)
- Testing
- Darunavir/Ritonavir (DRV/r), Lopinavir in fixed combination with Ritonavir, Zidovudine
- Where
- 17 sites in Germany
- Volunteers
- 312 people
- Sponsor
- Janssen-Cilag G.m.b.H
Cytomegalovirus Infections
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a…
- Trial name
- NCT00497796
- Testing
- maribavir, ganciclovir
- Where
- 55 sites in United States
- Volunteers
- 307 people
- Sponsor
- Shire
Infections, Rotavirus
To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)
To provide specific data on immunogenicity of GSK Biologicals' HRV liquid vaccine, when co-administered with the routine Expanded Program of Immunization (EPI) in Vietnam.
- Trial name
- NCT00345956
- Testing
- Human rotavirus liquid vaccine
- Where
- 2 sites in Vietnam
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT00156910
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 679 people
- Sponsor
- Allergan
Acellular Pertussis, Diphtheria
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
GSK Biologicals' dTpa vaccine has recently been approved by the US Food and Drug Administration (FDA) for booster vaccination of adolescents aged 10 to 18 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00346073
- Testing
- Boostrix™, ADACEL®
- Where
- 42 sites in United States
- Volunteers
- 2,337 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline